Skip to main content

06-10-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: A primary care view of the REWIND trial

Conference coverage direct to your inbox

Kamlesh Khunti discusses what the REWIND findings mean for doctors working with people with type 2 diabetes and high cardiovascular risk in primary care (1:43).

More on this topic

Back to the conference hub

Related topics

Image Credits